Eplivanserin

Eplivanserin

Systematic (IUPAC) name
(Z,E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-2-propen-1-one O-[2-(dimethylamino)ethyl]oxime
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	130579-75-8 Template:CAS (fumarate)
ATC code	none
PubChem	CID: 5493160
ChemSpider	13267837
UNII	3CO94WO6DJ Y
KEGG	D10006 Y
Chemical data
Formula	C19H21FN2O2
Molecular mass	328.381 g/mol
SMILES c2cc(O)ccc2\C=C\C(=N\OCCN(C)C)\c1ccccc1F
InChI InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19- Key:VAIOZOCLKVMIMN-PRJWTAEASA-N
(verify)

Eplivanserin (SR-46,349; planned trade name Ciltyri) was an experimental drug for the treatment of insomnia which was being developed by Sanofi Aventis.

Sanofi Aventis announced in December 2009 that it was withdrawing its application for approval of eplivanserin from both the U.S. Food and Drug Administration and the European Medicines Agency.

Mechanism of action

Eplivanserin is an inverse agonist on the serotonin receptor subtype 5-HT_2A. In contrast to older sedating drugs acting on 5-HT_2A receptors (e.g., mirtazapine, clozapine, risperidone), eplivanserin has practically no affinity to dopamine, histamine and adrenergic receptors.

Study results

In a placebo controlled Phase II clinical trial with 351 subjects, eplivanserin reduced the sleep latency by 39 minutes (versus 26 minutes under placebo).

See also

• Pimavanserin
• Volinanserin